Evidence from previous systematic reviews suggested that imatinib, vemurafenib, and rituximab are the top three targeted therapies that most commonly cause SJS/TEN, while epidermal growth factor receptor inhibitors are the class of agents that most commonly induce SJS/TEN (35). The gene discussed is EGFR; the disease is toxic epidermal necrolysis.